4
11
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T21954 |
EGFR/ErbB-2/ErbB-4 inhibitor-2
EGFR/ErbB2 Inhibitor |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EGFR/ErbB-2/ErbB-4 inhibitor-2 (EGFR/ErbB2 Inhibitor) 是EGFR 和ErbB 的抑制剂,对EGFR、ErbB2 和 ErbB4 的IC50分别为 0.017、0.08 和 1.91 μM。 | |||
T4014 |
CP-724714
CP724714,CP 724714 |
Apoptosis; EGFR | Angiogenesis; Apoptosis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
CP-724714 (CP724714) 是一种高效、选择性口服活性的 ErbB2 (HER2)酪氨酸激酶抑制剂,IC50为 10 nM。它能抑制完整细胞中 ErbB2 受体的自磷酸化,具有抗肿瘤活性。它对 EGFR 激酶有明显的选择性,IC50值为6400 nM。 | |||
T2116 |
AEE788
NVP-AEE 788 |
Apoptosis; EGFR; c-Fms; FLT; Bcr-Abl | Angiogenesis; Apoptosis; Cytoskeletal Signaling; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
AEE788 (NVP-AEE 788)是EGFR 和ErbB2的抑制剂,IC50值分别为2和6 nM。它已用于研究癌症、多形性胶质母细胞瘤以及脑和中枢神经系统肿瘤治疗的试验。 | |||
T6734 |
WZ8040
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
WZ8040 是一种新型突变选择性不可逆 EGFRT790M 抑制剂,可抑制EGFR 磷酸化。它对突变型EGFR 的活性是野生型EGFR 的100倍以上。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-02469 |
HER2/ERBB2 Protein, Mouse, Recombinant (hFc)
EGFR2,c-erbB2,l11Jus8, |
Mouse | HEK293 Cells |
HER2/ERBB2 Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 96.7 kDa and the accession number is P70424. | |||
TMPY-02314 |
HER2/ERBB2 Protein, Mouse, Recombinant (His)
HER2,c-erbB2,erb-b2<... |
Mouse | HEK293 Cells |
HER2/ERBB2 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 71.1 kDa and the accession number is P70424. | |||
TMPJ-00791 |
HER2/ERBB2 Protein, Rat, Recombinant (E. coli, His)
p185erbB2,Epidermal growth factor... |
Rat | E. coli |
ERBB2 belongs to the protein kinase superfamily, Tyr protein kinase family and EGF receptor subfamily. It contains a protein kinase domain. ERBB2 is widely expressed in epithelial cells, and amplification and/or overexpression of ErbB2 has been reported associated with malignancy and a poor prognosis in numerous carcinomas, including breast, prostate and ovarian cancers. Rat ERBB2 is an essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. ErbB... | |||
TMPJ-00778 |
HER2/ERBB2 Protein, Human, Recombinant (His)
TKR1,Metastatic lymph node gene 19 protein,ERBB... |
Human | HEK293 Cells |
HER2/ERBB2 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with C-6xHis tag. The predicted molecular weight is 90-120 KDa and the accession number is P04626. | |||
TMPK-00430 |
HER2/ERBB2 Domain 4 Protein, Human, Recombinant (His & Avi), Biotinylated
MLN19,HERV7Q,HERVW,MLN 19,TKR1,herstatin,ENVW,EGFR2... |
Human | HEK293 Cells |
HER2/ERBB2 Domain 4 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 18.5 kDa and the accession number is P04626-1. | |||
TMPJ-00777 |
HER2/ERBB2 Protein, Human, Recombinant (aa 23-652, hFc)
TKR1,Proto-oncogene Neu,EGFR2,Tyrosine kin... |
Human | HEK293 Cells |
HER2/ERBB2 Protein, Human, Recombinant (aa 23-652, hFc) is expressed in HEK293 mammalian cells with C-Fc tag. The predicted molecular weight is 120-145 KDa and the accession number is P04626. | |||
TMPK-00429 |
HER2/ERBB2 Domain 4 Protein, Human, Recombinant (His & Avi)
HERV7Q,HER-2,HER2,NGL,EGFR2,ENVW,... |
Human | HEK293 Cells |
HER2/ERBB2 Domain 4 Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 18.5 kDa and the accession number is P04626-1. | |||
TMPJ-00776 |
HER2/ERBB2 Protein, Human, Recombinant (hFc & Avi), Biotinylated
Tyrosine kinase-type cell surface rec<... |
Human | HEK293 Cells |
HER2/ERBB2 Protein, Human, Recombinant (hFc & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-Fc-Avi tag. The predicted molecular weight is 120-140 KDa and the accession number is P04626. | |||
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,CFC2 |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS<... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |